Compare retatrutide research vials, product-specific CoA availability, and Canadian shipping. Helix North lists lyophilized material for laboratory use only. Research listings are not approved medicines or a route to self-treatment.
Lab-tested research doses · flat $30 CAD Xpresspost · CoAs where available
Single vial or 10-vial kit for Retatrutide 10mg and Retatrutide 20mg; other sizes ship as 10-vial kits.
Section 01 — Definition
Retatrutide is a synthetic peptide studied as a triple agonist — it engages three receptors at once: GLP-1, GIP, and glucagon. That third target, the glucagon receptor, is what separates it from the incretin peptides that came before it and is the reason it draws sustained interest in metabolic research.
In research discussion the name is routinely shortened to “reta”, and the two terms are interchangeable — reta, reta peptide, and retatrutide all refer to the same compound, LY3437943. We use the full name throughout this page for precision, but the abbreviation is what you will most often see in forums and vendor listings.
The class has expanded step by step. Semaglutide acts on a single receptor (GLP-1). Tirzepatide added a second (GIP) to become a dual agonist. Retatrutide adds a third (glucagon), which is why it is sometimes described informally as a “GLP-3” peptide (often written GLP3) — shorthand for triple-agonist activity, not a distinct new receptor.
Retatrutide remains investigational. Lilly reports that it has no regulatory approval and warns against taking products claiming to be retatrutide outside its trials. Our approval-status explainer introduces the regulatory process; the official source is the reference for current status.
Helix North supplies retatrutide strictly as a lyophilized research material for in-vitro and laboratory use. Everything on this page is written for research handling and sourcing — it is not dosing guidance and not for human use.
One agonist became two, two became three. Retatrutide is the triple-agonist step in the incretin research lineage.
Section 02 — Mechanism
What makes retatrutide distinct is the number of receptor pathways it engages. Each receptor sits on a different arm of metabolic signalling, and the research interest lies in what happens when all three are activated together rather than one at a time.
| Compound | Receptors | Class |
|---|---|---|
| Semaglutide | GLP-1 | Single agonist |
| Tirzepatide | GLP-1, GIP | Dual agonist |
| Retatrutide | GLP-1, GIP, glucagon | Triple agonist |
The glucagon receptor is the differentiator. In the single- and dual-agonist compounds it is absent; in retatrutide it is the third pathway, which is why the compound is studied as its own category rather than an incremental version of tirzepatide.
That third pathway also shapes what the trials measured. The published Phase 2 work reported the largest body-weight reduction of any compound in the class, and it recorded glucagon-linked observations — small heart-rate changes among them — that the single- and dual-agonist compounds do not produce. Our summaries of the retatrutide weight-loss research and the retatrutide side-effect profile work through both sides of that dataset.
For the full mechanism, our triple-agonist explainer and GLP-1 receptor agonist primer go deeper, and the retatrutide vs tirzepatide and three-way comparison articles set it against the rest of the class. If the brand names are the confusing part, retatrutide vs Zepbound, Wegovy and Ozempic decodes which compound sits inside each.
For how those outcomes unfolded over the 48 weeks of the trial — onset, the shape of the curve, and whether it plateaued — see our retatrutide timeline breakdown.
Section 03 — Product
Retatrutide is stocked in three vial sizes — 10 mg, 20 mg, and 30 mg — so a protocol can match concentration and quantity to its needs rather than over- or under-buying. Each vial ships lyophilized for research handling.
Every lot is sent to an independent third-party laboratory for HPLC purity analysis, with identity confirmed by mass spectrometry. We do not release a lot below 99 percent purity. Where we hold a CoA, its lot number, chromatogram, and calculated purity are published on the relevant product page before ordering.
Choose a vial size below, or read how each lot is tested on our lab testing and CoA page.
Section 04 — Handling
A bottle labelled “reconstitution solution” does not establish compatibility with retatrutide. Check its ingredients, preservative concentration, and the formulation-specific laboratory instructions before choosing a diluent.
Our retatrutide reconstitution and diluent-compatibility guide explains the checks, laboratory concentration calculations, and the limits of storage claims. A clear solution alone cannot verify identity, potency, or sterility.
The BAC water buying guide lists reagent sizes separately. Neither a water product label nor a concentration calculator establishes that a retatrutide formulation is suitable for injection or clinical use.
Section 05 — Sourcing
For laboratory procurement, Helix North lists 5 mg, 10 mg, 20 mg, and 30 mg retatrutide research vials. Open the product page to check its current stock status, CAD price, and documentation before ordering. These listings are for laboratory research, not personal treatment.
CoAs are published on product pages where available; not every product has one. If your lab needs a report for a particular lot, ask us to confirm the available documentation before purchase. A report for another vial size or lot is not proof of the material in your order.
Retatrutide is not an approved medicine in Canada as of September 12, 2026. Lilly Canada distinguishes investigational retatrutide from authorized medicines. An online research listing does not establish medical approval, safety, or eligibility for a clinical trial.
Discuss approved treatment options and potential clinical-trial participation with a licensed healthcare professional. Trial eligibility, recruiting status, and location must be confirmed with the study team. Do not use research vials for self-treatment.
Health Canada warns against unauthorized injectable peptides, including retatrutide. A “research use only” label does not create a regulatory exemption.
Helix North ships domestically by Canada Post Xpresspost with tracking and flat $30 CAD shipping. Check the regional delivery estimates and shipping policy; estimates are not guaranteed arrival dates. For supplier-selection criteria, use our Canadian research peptide sourcing guide.
Section 06 — Common questions
Helix North lists 5, 10, 20, and 30 mg retatrutide vials for laboratory research. Check the individual product page for current stock, CAD pricing, and CoA availability. Not every product has a published CoA. Research listings are not approved medicines and must not be used for self-treatment.
Retatrutide is not an approved medicine in Canada as of September 12, 2026. Lilly reports that it remains investigational. A research catalog listing does not establish medical approval or access to a clinical trial. See the sourcing section above for official sources.
Talk to a licensed healthcare professional about approved treatments and clinical-trial options. Confirm eligibility and recruiting status with the study team. Do not use research vials for self-treatment.
Health Canada warns against unauthorized injectable retatrutide and states that a research-use label does not create a regulatory exemption. Laboratory purchasers must confirm the requirements for their intended work; this page is not legal advice.
Yes. “Reta” is simply the common abbreviation for retatrutide, and “reta peptide” means the same thing — all three refer to the same compound, Eli Lilly development code LY3437943. The shortened form dominates forum and vendor usage while the full name is used in the published literature. There is no difference in the compound itself, and any claim that reta and retatrutide are separate products is incorrect.
Retatrutide is a synthetic triple agonist peptide that targets three receptors at once — GLP-1, GIP, and glucagon. Because it extends the incretin-agonist class beyond single-receptor (semaglutide) and dual-receptor (tirzepatide) compounds, it is informally described as a “GLP-3” peptide. The label is a shorthand for triple-agonist activity, not a distinct fourth receptor. Our triple-agonist explainer covers the mechanism in depth.
Yes. “GLP-3” is an informal nickname for retatrutide (reta), the triple GLP-1/GIP/glucagon receptor agonist, Eli Lilly development code LY3437943. There is no GLP-3 hormone or receptor — the label is shorthand for triple-agonist activity, and Lilly itself describes it as scientifically inaccurate. Vendor listings marked “GLP-3”, “GLP-3 RT”, or “RTA” are describing this same compound.
The difference is receptor count. Tirzepatide is a dual agonist acting on GLP-1 and GIP; retatrutide is a triple agonist adding glucagon-receptor activity. Both are supplied by Helix North as third-party-tested lyophilized research peptides, with Certificates of Analysis linked where available. See our retatrutide vs tirzepatide comparison for the full research profile. We do not provide dosing, protocol, or clinical guidance for either compound.
The catalog lists 5, 10, 20, and 30 mg lyophilized research vials, plus a separately listed 5 mg and BAC water bundle. Current availability and included items are shown on each product page. CoAs are linked where available.
Start with formulation-specific laboratory instructions and a compatible diluent. A generic reconstitution-solution label is not enough. Our retatrutide reconstitution guide covers compatibility checks and concentration arithmetic, not instructions for human administration.
Follow the storage conditions and use period validated for the specific formulation and laboratory protocol. BAC water does not establish retatrutide stability or a universal storage life. If the documentation does not specify conditions, ask the supplier before preparing the stock.
Every retatrutide lot is third-party tested to at least 99 percent purity by HPLC, with identity confirmed by mass spectrometry. Where Helix North holds a Certificate of Analysis, the lot number and chromatogram are published on the relevant product page before ordering. A lot that falls below specification is not released.
Retatrutide ships lyophilized and stable at ambient temperature by Canada Post Xpresspost anywhere in Canada, in plain unmarked packaging with tracking. Transit is typically 2 to 4 business days to Ontario and Quebec, 2 to 3 to the Prairies, and 1 to 2 in British Columbia, at a flat $30. Because it never leaves the country there is no customs clearance.
Yes. Alongside retatrutide, the GLP research line includes tirzepatide and cagrilintide. See the GLP-1 research peptides hub for the full range, or our three-way comparison of retatrutide, semaglutide, and tirzepatide.
Looking for something broader? Our most-asked retatrutide questions article answers what circulates most often online, separating published trial findings from anecdote.
Choose a third-party-tested 10, 20, or 30 mg vial, or browse the full GLP research line. Questions about CoA availability, lots, or bulk quantities — get in touch.